EA201070553A1 - Антитела к гепцидину и варианты их применения - Google Patents

Антитела к гепцидину и варианты их применения

Info

Publication number
EA201070553A1
EA201070553A1 EA201070553A EA201070553A EA201070553A1 EA 201070553 A1 EA201070553 A1 EA 201070553A1 EA 201070553 A EA201070553 A EA 201070553A EA 201070553 A EA201070553 A EA 201070553A EA 201070553 A1 EA201070553 A1 EA 201070553A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepcidin
antibodies
variants
human hepcidin
application
Prior art date
Application number
EA201070553A
Other languages
English (en)
Other versions
EA023406B1 (ru
Inventor
Юйпин Энтони Цай
Деннис Патрик Гейтли
Лухун Хе
Донмьенн Доэн Льюнг
Пэн Луань
Барбара Энн Свэнсон
Ин Тан
Деррик Райан Уитчер
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40383701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201070553(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201070553A1 publication Critical patent/EA201070553A1/ru
Publication of EA023406B1 publication Critical patent/EA023406B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Предложены моноклональные антитела, которые избирательно связывают человеческий гепцидин-25 и характеризуются высоким сродством к гепцидину-25 человека и выраженной способностью к нейтрализации зрелого гепцидина человека. Антитела согласно изобретению можно применять в терапии для повышения уровня железа в сыворотке, числа ретикулоцитов, эритроцитов, гемоглобина и/или гематокрита у человека, а также для лечения и диагностики заболеваний, опосредуемых гепцидином, например, анемии, у субъекта.
EA201070553A 2007-11-02 2008-10-29 Антитела к гепцидину и варианты их применения EA023406B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98491007P 2007-11-02 2007-11-02
PCT/US2008/081493 WO2009058797A1 (en) 2007-11-02 2008-10-29 Anti-hepcidin antibodies and uses thereof

Publications (2)

Publication Number Publication Date
EA201070553A1 true EA201070553A1 (ru) 2010-10-29
EA023406B1 EA023406B1 (ru) 2016-06-30

Family

ID=40383701

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070553A EA023406B1 (ru) 2007-11-02 2008-10-29 Антитела к гепцидину и варианты их применения

Country Status (35)

Country Link
US (3) US7820163B2 (ru)
EP (2) EP2527368B1 (ru)
JP (1) JP5469076B2 (ru)
KR (2) KR101335059B1 (ru)
CN (1) CN103492414B (ru)
AR (1) AR069062A1 (ru)
AU (1) AU2008318850B2 (ru)
BR (1) BRPI0819211A2 (ru)
CA (1) CA2704527C (ru)
CL (2) CL2008003190A1 (ru)
CO (1) CO6231037A2 (ru)
CR (1) CR11414A (ru)
CY (1) CY1113630T1 (ru)
DK (1) DK2209806T3 (ru)
DO (2) DOP2010000123A (ru)
EA (1) EA023406B1 (ru)
ES (1) ES2392123T3 (ru)
HK (1) HK1142341A1 (ru)
HR (1) HRP20120870T1 (ru)
IL (1) IL205355A (ru)
JO (1) JO2828B1 (ru)
MA (1) MA31886B1 (ru)
MX (1) MX2010004841A (ru)
MY (1) MY155708A (ru)
NZ (2) NZ598391A (ru)
PE (1) PE20091261A1 (ru)
PL (1) PL2209806T3 (ru)
PT (1) PT2209806E (ru)
RS (1) RS52592B (ru)
SI (1) SI2209806T1 (ru)
TN (1) TN2010000201A1 (ru)
TW (1) TWI409276B (ru)
UA (1) UA98983C2 (ru)
WO (1) WO2009058797A1 (ru)
ZA (1) ZA201003025B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053268A1 (en) * 2006-10-17 2011-03-03 Naohisa Tomosugi Method for diagnosis of abnormal iron metabolism using active hepcidin as indicator
TW201307390A (zh) 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
JPWO2008146903A1 (ja) * 2007-05-31 2010-08-19 直久 友杉 活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法
CL2008003190A1 (es) * 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
EP2294087B1 (en) * 2008-05-01 2014-05-14 Amgen, Inc. Anti-hepcidin antibodies and methods of use
CA2733497C (en) * 2008-08-06 2015-06-02 Eli Lilly And Company Anti-hepcidin-25 selective antibodies and uses thereof
DE102009034150A1 (de) * 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
AR077892A1 (es) 2009-08-20 2011-09-28 Vifor Int Ag Quinolinas antagonistas de la hepcidina
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
US20120214798A1 (en) 2009-09-07 2012-08-23 Vifor (International) Ag Novel Ethanediamone Hepcidine Antagonists
WO2011029832A1 (de) 2009-09-09 2011-03-17 Vifor (International) Ag Neue thiazol- und oxazol-hepcidin-antagonisten
WO2011071368A1 (en) 2009-12-11 2011-06-16 Umc St. Radboud Method for measuring hepcidin
RU2625011C2 (ru) 2010-08-16 2017-07-11 Пиерис АГ Белки, связывающиеся с гепсидином
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
AU2012350654C1 (en) 2011-12-12 2018-05-10 Pieris Ag Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
NZ631098A (en) * 2013-03-15 2016-09-30 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
CN104945497B (zh) * 2014-11-21 2018-04-03 南京国龙生物科技有限公司 一种新型抗菌肽Hep‑W及其制备方法和应用
CA2977648C (en) 2015-02-24 2024-01-02 Rpeptide, Llc Anti-tau antibodies
EP3268027B1 (en) 2015-03-13 2022-11-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Hepcidin antagonists for use in the treatment of inflammation
TWI789343B (zh) 2016-02-01 2023-01-11 丹麥商碩騰丹麥有限公司 微流體分析系統、執行分析的微流體匣及方法
WO2018234538A1 (en) 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTAGONIST OR AGONIST OF HEPCIDINE FOR USE IN THE TREATMENT OF DYSREGULATION OF MO AND / OR MN METABOLISM
ES2759622T3 (es) * 2017-10-02 2020-05-11 Certest Biotec S L Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6262247B1 (en) 1999-08-30 2001-07-17 Incyte Genomics, Inc. Polycyclic aromatic hydrocarbon induced molecules
ES2693050T3 (es) 2001-05-25 2018-12-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uso de hepcidina para preparar un medicamento para tratar trastornos de la homeostasis del hierro
CN1173737C (zh) 2002-10-21 2004-11-03 钱忠明 Hepcidin(海魄喜定)在制药中的应用
US8017737B2 (en) * 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US7749713B2 (en) * 2002-11-19 2010-07-06 Hasan Kulaksiz Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
CA2537668A1 (en) 2003-09-29 2005-04-14 Biosite Incorporated Methods and compositions for the diagnosis of sepsis
US7723063B2 (en) 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
WO2006046935A1 (en) 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc Methods of optimizing antibody variable region binding affinity
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
KR101310000B1 (ko) 2005-03-11 2013-09-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘
TW201307390A (zh) * 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
ES2385772T3 (es) 2007-10-02 2012-07-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos específicos para la hepcidina humana
CL2008003190A1 (es) * 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
EP2294087B1 (en) 2008-05-01 2014-05-14 Amgen, Inc. Anti-hepcidin antibodies and methods of use
CA2733497C (en) * 2008-08-06 2015-06-02 Eli Lilly And Company Anti-hepcidin-25 selective antibodies and uses thereof

Also Published As

Publication number Publication date
KR101335059B1 (ko) 2013-12-11
KR20120107145A (ko) 2012-09-28
RS52592B (en) 2013-04-30
CL2008003190A1 (es) 2009-09-04
US7820163B2 (en) 2010-10-26
CY1113630T1 (el) 2016-06-22
TW200927759A (en) 2009-07-01
DOP2013000205A (es) 2013-12-15
HK1142341A1 (en) 2010-12-03
HRP20120870T1 (hr) 2012-11-30
EA023406B1 (ru) 2016-06-30
PL2209806T3 (pl) 2013-01-31
AR069062A1 (es) 2009-12-23
CL2012001710A1 (es) 2013-04-12
JO2828B1 (en) 2014-09-15
US20130164304A1 (en) 2013-06-27
DOP2010000123A (es) 2010-08-15
EP2527368B1 (en) 2016-08-24
TWI409276B (zh) 2013-09-21
SI2209806T1 (sl) 2012-11-30
US20090136495A1 (en) 2009-05-28
DK2209806T3 (da) 2012-09-17
PT2209806E (pt) 2012-10-03
IL205355A (en) 2015-05-31
IL205355A0 (en) 2010-12-30
EP2527368A1 (en) 2012-11-28
JP5469076B2 (ja) 2014-04-09
WO2009058797A1 (en) 2009-05-07
CN103492414A (zh) 2014-01-01
MY155708A (en) 2015-11-13
KR20100067682A (ko) 2010-06-21
AU2008318850B2 (en) 2014-05-29
MX2010004841A (es) 2010-07-30
CN103492414B (zh) 2016-04-13
UA98983C2 (ru) 2012-07-10
NZ584997A (en) 2012-06-29
US8329174B2 (en) 2012-12-11
CO6231037A2 (es) 2010-12-20
TN2010000201A1 (en) 2011-11-11
BRPI0819211A2 (pt) 2015-06-16
CA2704527C (en) 2015-12-15
MA31886B1 (fr) 2010-12-01
CR11414A (es) 2010-08-05
PE20091261A1 (es) 2009-08-17
EP2209806A1 (en) 2010-07-28
JP2011502482A (ja) 2011-01-27
ZA201003025B (en) 2011-11-30
ES2392123T3 (es) 2012-12-04
US8765129B2 (en) 2014-07-01
AU2008318850A1 (en) 2009-05-07
EP2209806B1 (en) 2012-08-22
CA2704527A1 (en) 2009-05-07
NZ598391A (en) 2013-07-26
US20110027261A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
EA201070553A1 (ru) Антитела к гепцидину и варианты их применения
EA201170312A1 (ru) Селективные антитела к гепцидину-25 и их применение
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201100694A1 (ru) Антитело к cd38 человека и его применение
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
EA201190018A1 (ru) Миостатинсвязывающие белки
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
EA201590370A1 (ru) Антитела к pcsk9 c ph-зависимыми характеристиками связывания
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
WO2005110474A3 (en) HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EA200870021A1 (ru) Человеческие моноклональные антитела к фукозил-gm1 и способы применения анти-фукозил-gm1 антител
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
TR201900764T4 (tr) LAG-3 ve terapötik antikorlar içeren bileşimler ve bunların kanser tedavisinde kullanımı.
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
EA201170716A1 (ru) Антитела к с-мет
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
EA201000424A1 (ru) Антитела к il-23
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
IL187321A (en) Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation
EA201300125A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний желудочно-кишечного тракта функциональной этиологии

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU